Patent ID: 8841335

Claim:
A method for treating a disease selected from the group consisting of stroke, Alzheimer's disease, Huntington's disease, Pick's disease, Creutzfeld-Jacob's disease, Parkinson-ALS-dementia complex, Wilson's disease, multiple sclerosis, progressive supranuclear palsy, neuropathic pain-related bipolar disorders, corticobasal degeneration, schizophrenia, attention deficit hyperactivity disorder (ADHD), dementia, amyotrophic lateral sclerosis, retinal disease, epilepsy, apoplexy, transient ischemic attacks, myocardial ischemia, muscle ischemia, ischemia caused by surgical technique regarding extended suspension of blood flow to brain, head injury, spinal cord injury, hypoxia and depression, comprising: administering to a subject in need of such treatment a therapeutically effective amount of a compound of Formula I, a pharmaceutically acceptable salt, an isomer, a solvate, or a hydrate thereof, or any combination thereof: wherein R is selected from the group consisting of substituted or unsubstituted C 1 -C 15 arylalkyl, substituted or unsubstituted C 1 -C 15 heteroarylalkyl, and substituted or unsubstituted, linear, branched or cyclic C 1 -C 10 alkyl; Y is selected from the group consisting of O and —N—R 1 ; R 1 is at least one selected from the group consisting of —H and linear or branched C 1 -C 3 alkyl; R 2 is selected from the group consisting of —H and halo; A is selected from the group consisting of N, O, and S; B is C or N; Z is selected from the group consisting of carbamate, —OC(═O)NR 3 R 4 , —NH 2 , —NR 5 R 6 , —NC(═NH)NH 2 , and —NC(═O)NH 2 ; each of R 3 and R 4 is independently selected from the group consisting of C 1 -C 5 alkyl substituted with at least one selected from the group consisting of —H, —NH 2 and —NR 7 R 8 , unsubstituted C 1 -C 5 alkyl, heterocyclic group substituted with C 1 -C 3 alkyl, and unsubstituted heterocyclic group, or R 3 and R 4 are taken together to form a 5- or 7-membered heterocyclic group substituted with C 1 -C 5 alkyl or unsubstituted 5- to 7-membered heterocyclic group; each of R 5 and R 6 is independently selected from the group consisting of —H, C 2 -C 3 alkenyl, C 2 -C 3 alkynyl, and linear or branched C 1 -C 7 alkyl unsubstituted or substituted with at least one selected from the group consisting of —OH, —C(O)NH 2 , C 1 -C 3 alkoxy and carbamate, or R 5 and R 6 are taken together to form substituted or unsubstituted aliphatic cyclic amine or substituted or unsubstituted aromatic cyclic amine; each of R 7 and R 8 is independently at least one selected from the group consisting of —H and linear or branched C 1 -C 3 alkyl; m is an integer in the range of 0 to 4; and n is an integer in the range of 0 to 5.